The National Lung Matrix Trial of personalized therapy in lung cancer-Reference-Cited by-同舟云学术

The National Lung Matrix Trial of personalized therapy in lung cancer

Published:2020-07-15 Issue:7818 Volume:583 Page:807-812
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Middleton Gary^ORCID,Fletcher Peter,Popat Sanjay^ORCID,Savage Joshua^ORCID,Summers Yvonne,Greystoke Alastair,Gilligan David,Cave Judith,O’Rourke Noelle,Brewster Alison,Toy Elizabeth,Spicer James,Jain Pooja,Dangoor Adam^ORCID,Mackean Melanie,Forster Martin,Farley Amanda,Wherton Dee,Mehmi Manita^ORCID,Sharpe Rowena,Mills Tara C.,Cerone Maria Antonietta,Yap Timothy A.^ORCID,Watkins Thomas B. K.,Lim Emilia,Swanton Charles^ORCID,Billingham Lucinda

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-020-2481-8.pdf

Reference32 articles.

1. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).

2. Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863–870 (2012).

3. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).

4. Carr, T. H. et al. Defining actionable mutations for oncology therapeutic development. Nat. Rev. Cancer 16, 319–329 (2016).

5. Berry, S. M., Carlin, B. P., Lee, J. J. & Muller, P. Bayesian Adaptive Methods for Clinical Trials (CRC, 2010).

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC;Clinical Cancer Research;2024-07-17

2. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis;Clinical Radiology;2024-07

3. Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and Strategies;American Society of Clinical Oncology Educational Book;2024-06

4. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-04-24

5. Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study;International Journal of Gynecologic Cancer;2024-04-23